HTLV-1感染与不良健康结局的关联:流行病学研究的系统综述与荟萃分析
该系统综述与荟萃分析检索Embase、MEDLINE等数据库至2018年7月,纳入39项比较HTLV-1感染者与未感染者死亡或发病的研究。
核心结论
- HTLV-1感染者全因死亡风险升高,但现有发病研究不能完全解释该死亡风险。
- HTLV-1关联的疾病谱可能比通常认识的更广,心血管、脑血管和代谢疾病方面存在研究空白。
研究设计与样本
- 系统综述与荟萃分析,检索Embase、MEDLINE、MEDLINE In-Process和Global Health从建库至2018年7月。
- 纳入比较HTLV-1感染者与未感染者死亡或发病的队列、病例对照和对照横断面研究,最终纳入39项研究,涉及42种临床状况。
主要发现
- 另有14种疾病在单项研究中显示与HTLV-1显著相关或风险 substantially 升高。
临床怎么用
- 对HTLV-1感染者应关注全因死亡风险升高,并警惕脂溢性皮炎、干燥综合征等关联疾病。
- 临床评估HTLV-1感染者时需注意胃癌风险可能较低,但需结合个体情况。
局限性
- 研究仅检索至2018年7月,可能未纳入后续证据。
- 许多疾病关联仅来自单项研究,证据强度有限。
- 心血管、脑血管和代谢疾病方面存在显著研究空白。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human T-cell lymphotropic virus type 1 (HTLV-1) is a human retrovirus that causes a lifelong infection. Several diseases, including an aggressive form of leukaemia, have been designated as associated with HTLV-1, whereby having HTLV-1 is a necessary condition for diagnosis. Beyond these diseases, there is uncertainty about other health effects of HTLV-1. We aimed to synthesise evidence from epidemiological studies on associations between health outcomes and HTLV-1. METHODS: For this systematic review and meta-analysis, we searched Embase, MEDLINE, MEDLINE In-Process, and Global Health for publications from their inception to July, 2018. We included cohort, case-control, and controlled cross-sectional studies that compared mortality or morbidity between people with and without HTLV-1. We excluded studies of psychiatric conditions, of symptoms or clinical findings only, of people who had undergone blood transfusion or organ transplant, and of population groups defined by a behavioural characteristic putting them at increased risk of co-infection with another virus. We extracted the risk estimates (relative risks [RRs] or odds ratios [ORs]) that reflected the greatest degree of control for potential confounders. We did a random-effects meta-analysis for groups of effect estimates where case ascertainment methods, age groups, and confounders were similar, presenting pooled estimates with 95% CIs and prediction intervals. FINDINGS: Of the 3318 identified studies, 39 met the inclusion criteria, examining 42 clinical conditions between them. The adjusted risk of death due to any cause was higher in people with HTLV-1 when compared with HTLV-1-negative counterparts (RR 1·57, 95% CI 1·37-1·80). From meta-analysis, HTLV-1 was associated with increased odds of seborrheic dermatitis (OR 3·95, 95% CI 1·99-7·81), Sjogren's syndrome (3·25, 1·85-5·70), and, inversely, with lower relative risk of gastric cancer (RR 0·45, 0·28-0·71). There were a further 14 diseases with significant associations or substantially elevated risk with HTLV-1 from single studies (eczema [children]; bronchiectasis, bronchitis and bronchiolitis [analysed together]; asthma [males]; fibromyalgia; rheumatoid arthritis; arthritis; tuberculosis; kidney and bladder infections; dermatophytosis; community acquired pneumonia; strongyloides hyperinfection syndrome; liver cancer; lymphoma other than adult T-cell leukaemia-lymphoma; and cervical cancer). INTERPRETATION: There is a broad range of diseases studied in association with HTLV-1. However, the elevated risk for death among people with HTLV-1 is not explained by available studies of morbidity. Many of the diseases shown to be associated with HTLV-1 are not fatal, and those that are (eg, leukaemia) occur too rarely to account for the observed mortality effect. There are substantial research gaps in relation to HTLV-1 and cardiovascular, cerebrovascular, and metabolic disease. The burden of disease associated with the virus might be broader than generally recognised. FUNDING: Commonwealth Department of Health, Australia.
引用
- Schierhout G, McGregor S, Gessain A, et al. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. Lancet Infect Dis. 2019. PMID: 31648940. doi:10.1016/S1473-3099(19)30402-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。